Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment

Basit Öğe Kaydı
dc.authorid0000-0002-9782-6807
dc.authorid0000-0001-8857-2983
dc.contributor.authorAcar, Caner
dc.contributor.authorYuksel, Haydar Cagatay
dc.contributor.authorSahin, Gokhan
dc.contributor.authorAcar, Fatma Pinar
dc.contributor.authorTunbekici, Salih
dc.contributor.authorCelebi, Gulcin
dc.contributor.authorKaraca, Burcak
dc.date.accessioned2025-02-17T07:48:40Z
dc.date.available2025-02-17T07:48:40Z
dc.date.issued2024
dc.departmentEge Üniversitesi, Tıp Fakültesi, Dahili Bilimler Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.description.abstractImmune checkpoint inhibitors (ICIs) have significantly improved the five-year survival rate for advanced melanoma. However, many patients exhibit resistance to ICI therapy. This study evaluated the efficacy and prognostic factors of anti-PD-1 (Group A) and nivolumab-ipilimumab (Group B) therapy in patients with advanced melanoma who were resistant to prior ICI therapy. We conducted a retrospective analysis of 56 patients with advanced melanoma who had previously shown resistance to ICI therapy. In the Group A (who have previously shown resistance to anti-CTLA-4, n = 28), the objective response rate (ORR) was 42.9%, with a disease control rate (DCR) of 53%. In the Group B (previously shown resistance to anti-PD-1, n = 28), the ORR was 17.9%, and the DCR was 25%. The ORR was lower in two subgroups: patients who showed progression or relapse in the the initial radiological assessment of prior ICI therapy (ORR 10.5%) and patients who had previously received ICI in the adjuvant setting (ORR 8.3%). A Royal Marsden Hospital (RMH) score of 2-3 was a predictor of OS in both groups (Group A: HR 3.789, 95% CI 1.356-10.589, p = 0.011; Group B: HR 4.281, 95% CI 1.490-12.300, p = 0.007) and for PFS in the Group B (HR 3.167, 95% CI 1.062-9.442, p = 0.039). Anti-PD-1 therapy demonstrated efficacy following resistance to anti-CTLA-4, whereas combination ICI therapy showed lower response rates in patients resistant to anti-PD-1. Further studies are needed to confirm the RMH scores and other prognostic markers and to evaluate subgroups with lower efficacy of nivolumab-ipilimumab therapy.
dc.identifier.citationAcar, C., Yüksel, H. Ç., Şahin, G., Açar, F. P., Tünbekici, S., Çelebi, G., & Karaca, B. (2024). Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment. Discover. Oncology, 15(1), 813-14.
dc.identifier.doi10.1007/s12672-024-01702-w
dc.identifier.endpage14
dc.identifier.issn2730-6011
dc.identifier.issue1
dc.identifier.pmid39704850
dc.identifier.scopus2-s2.0-85212690868
dc.identifier.scopusqualityQ3
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.1007/s12672-024-01702-w
dc.identifier.urihttps://hdl.handle.net/11454/116065
dc.identifier.volume15
dc.identifier.wosWOS:001381662200005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAcar, Caner
dc.institutionauthorYuksel, Haydar Cagatay
dc.institutionauthorSahin, Gokhan
dc.institutionauthorAcar, Fatma Pinar
dc.institutionauthorTunbekici
dc.institutionauthorCelebi, Gulcin
dc.institutionauthorKaraca, Burcak
dc.institutionauthorid0000-0002-9782-6807
dc.institutionauthorid0000-0001-8857-2983
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofDiscover Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdvanced melanoma
dc.subjectResistance to ICI therapy
dc.subjectRMH score
dc.subjectSurvival
dc.titleEfficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu